Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Business Insights | The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

The emerging global market for biosimilars market grew 5.9% to reach a value of approximately $1bn in 2007. In the near term, four drug classes including erythropoietin, filgrastim, human growth hormone (hGH) and insulin, will drive the growth of biosimilars. Based on 2007 sales reported by IMS, biologics worth $25bn are expected to go off-patent by 2016, thus creating a significant market opportunity for biosimilars. This report provides an overview of the global biosimilars market, including its size, various business strategies adopted by the top 10 companies, current industry trends and future opportunities. It also discusses the biosimilars approval process in the US, EU and major semi-regulated markets. This report ranks the top 10 companies based on their sales in the 1H 2008 and maps their marketed and pipeline products across the off-patent biologics categories. It also highlights the factors that will either drive or inhibit the growth of biosimilars.

Published: April 2009 - Global. PDF
Table of Contents
Price: $3,835.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions